Table 2. 5-year CCSS and in relationship to IL-6 and IL-6R.

		5-year CCSS rates as time elapsed since surgery
	Baseline	1 Year	2 Year	3 Year	4 Year	5 Year
Cases, n	180	178	172	161	146	129
5-year CCSS rates (%)	79.7±3.1	75.3±3.4	74.3±3.5	75.0±3.6	78.8±3.6	83.8±3.6
Survival gain (%)a	—	−5.5±4.6	−1.0±4.9	+0.3±5.0	+3.8±5.1	+5.0±5.1
Survival gain (%)b	—	−5.5±4.6	−5.4±4.7	−4.7±4.7	−0.9±4.7	+4.1±4.7
Age at surgery (years)
⩽58	81.7±4.0	81.4±4.1	83.7±4.0	85.1±4.0	86.6±4.0	90.9±4.0
>58	77.3±4.7	68.1±5.4	63.5±5.7	63.4±5.9	68.8±6.2	74.6±6.2
P-value	0.545	0.094	0.007	0.004	0.019	0.007
Gender
Female	75.9±5.6	68.0±6.3	68.2±6.4	65.0±6.9	71.8±7.0	78.5±6.8
Male	81.6±3.6	79.1±3.9	77.3±4.1	80.1±4.0	82.2±4.1	86.2±4.2
P-value	0.395	0.127	0.217	0.071	0.197	0.220
pT
pT1+pT2	86.2±3.0	82.4±3.4	82.7±3.4	82.6±3.6	84.9±3.5	88.4±3.6
pT3+pT4	59.4±7.6	53.3±7.8	48.0±8.1	50.1±8.6	56.2±9.6	65.3±10.0
P-value	<0.001	<0.001	<0.001	<0.001	0.001	0.004
IL-6
Negative	88.2±3.2	83.9±3.7	80.7±4.0	81.1±4.0	85.0±3.9	85.0±4.0
Positive	67.2±5.6	62.6±6.0	64.0±6.3	63.8±6.9	66.7±7.3	66.3±8.0
P-value	0.001	0.001	0.012	0.020	0.011	0.027
Organ-confined subgroup (pT1+pT2)
Negative	94.8±2.5	90.7±3.3	89.3±3.6	87.8±3.8	89.6±3.7	90.9±3.6
Positive	73.2±6.2	69.5±6.7	72.1±6.7	72.7±7.3	76.0±7.2	83.3±7.8
P-value	<0.001	0.001	0.008	0.034	0.030	0.424
Locally advanced subgroup (pT3+pT4)
Negative	66.7±9.6	60.9±10.2	52.2±10.4	57.1±10.8	66.7±11.1	75.0±10.8
Positive	50.0±11.8	43.8±11.9	42.2±12.7	40.2±13.6	40.9±15.6	50.0±17.7
P-value	0.259	0.206	0.495	0.372	0.280	0.376
IL-6R
Negative	86.4±4.0	80.4±4.7	79.8±4.9	80.0±5.0	84.8±4.7	87.9±3.6
Positive	74.6±4.4	71.4±4.7	69.9±4.9	71.0±5.0	73.9±5.2	74.7±7.8
P-value	0.052	0.153	0.148	0.204	0.140	0.153
Organ-confined subgroup (pT1+pT2)
Negative	94.5±3.1	90.5±4.1	90.8±4.1	89.5±4.5	91.2±4.2	90.9±3.6
Positive	80.0±4.6	76.4±5.0	76.5±5.1	77.2±5.2	79.8±5.3	83.3±7.8
P-value	0.019	0.038	0.048	0.070	0.093	0.424
Locally advanced subgroup (pT3+pT4)
Negative	62.7±11.2	51.3±11.7	48.1±12.1	51.0±12.5	61.9±13.4	75.0±10.8
Positive	56.5±10.3	54.5±10.6	47.6±10.9	50.0±11.8	52.5±13.1	50.0±17.7
P-value	0.579	0.966	0.855	0.959	0.801	0.376

Abbreviations: CCSS=conditional cancer-specific survival; IL=interleukin; IL-6R=interleukin-6 receptor.

Survival rate estimations are expressed in percentage (%). S.e. are reported after plus-minus signs. For each value, the 95% confidence interval can be calculated as mean±1.96 × s.e. Log-rank test is used to assess the equality of survival distributions for the different levels of prognostic characteristics at each time point.

^aAs compared with baseline.

^bAs compared with previous time point.